During a Sinopharm trial in Peru.
-
ERNESTO BENAVIDES / AFP
Chinese laboratory Sinopharm announced on Wednesday that one of its Covid-19 vaccines was 79% effective, a figure lower than those claimed by its American competitors Pfizer (95%) and Moderna (94.1%).
Sinopharm is the first Chinese pharmacist to report figures on the effectiveness of a vaccine in preparation.
The Chinese authorities have nonetheless started to vaccinate more than a million people using products that they have not yet formally validated.
The British Astrazeneca, associated with the University of Oxford, for its part claimed an effectiveness rate of 70%, but which could reach 100% with two doses.
China, where the new coronavirus appeared a year ago, has put enormous resources into the development of vaccines, which it has promised to make "a global public good".
The country, which has practically stopped the epidemic on its soil, has had to conduct clinical tests in foreign countries where the circulation of the virus remains intense.
Five Chinese vaccines are therefore in phase 3 clinical trials. Sinopharm has not specifically specified whether these trials have been completed for this first vaccine.
The group said it had filed an application for approval of this first vaccine with the Chinese authorities.
World
UK approves AstraZeneca vaccine / University of Oxford
World
Cuba is developing its own vaccines
China
Vaccine
Vaccination
Covid 19
World
Coronavirus